These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32761768)

  • 1. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Zaccardi F; Jacquot E; Cortese V; Tyrer F; Seidu S; Davies MJ; Khunti K
    Diabetes Obes Metab; 2020 Dec; 22(12):2417-2426. PubMed ID: 32761768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
    Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
    Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes].
    Liu Z; Chen X; Zhao H; Zhan S; Sun F
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):424-430. PubMed ID: 38864127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
    Sharma M; Beckley N; Nazareth I; Petersen I
    BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
    Frias JP; Zimmer Z; Lam RLH; Amorin G; Ntabadde C; Iredale C; O'Neill EA; Engel SS; Kaufman KD; Makimura H; Crutchlow MF
    Diabetes Obes Metab; 2019 May; 21(5):1128-1135. PubMed ID: 30609212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
    Khaloo P; Asadi Komeleh S; Alemi H; Mansournia MA; Mohammadi A; Yadegar A; Afarideh M; Esteghamati S; Nakhjavani M; Esteghamati A
    J Endocrinol Invest; 2019 Jul; 42(7):851-857. PubMed ID: 30535871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
    Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
    BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study.
    Ku EJ; Jung KY; Kim YJ; Kim KM; Moon JH; Choi SH; Cho YM; Park KS; Jang HC; Lim S; Ahrén B
    PLoS One; 2015; 10(6):e0129477. PubMed ID: 26068661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
    Liu X; Wang L; Xing Y; Engel SS; Zeng L; Yao B; Xu W; Chen G; Zhang Y; Zhang R; Liu S; Weng J; Ji Q
    J Diabetes Investig; 2020 Nov; 11(6):1532-1541. PubMed ID: 32304283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Reasner C; Olansky L; Seck TL; Williams-Herman DE; Chen M; Terranella L; Johnson-Levonas AO; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
    Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
    Deng Y; Polley EC; Wallach JD; Dhruva SS; Herrin J; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Lyon TD; Shah ND; Ross JS; McCoy RG
    BMJ; 2022 Oct; 379():e070717. PubMed ID: 36191949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.